Table 1.
Name | Disease(s) or tests | Target Population | Coverage |
---|---|---|---|
Explicit Guarantees in Health GES (Law N° 19,966) [22] |
• Hemophilia • Cystic Fibrosis |
Individuals with suspected or confirmed diagnosis | Diagnostic confirmation (excludes molecular diagnosis and genetic counseling), follow up and therapies |
Coverage for High Cost medications and devices (Law 20.850 “Ley Ricarte Soto”) [20] |
• Mucopolysaccharidoses types I, II, VI • Tyrosinemia Type I • Gaucher Disease • Fabry Disease • Hereditary Angioedema • Pancreatic neuroendocrine tumors • Generalized dystonia • Multiple sclerosis • Primary immunodeficiency • Huntington disease • Epidermolysis bullosa • Amyotrophic lateral sclerosis • Bilateral severe-to-profound sensorineural hearing loss • Unresectable or metastatic gastrointestinal stromal tumors |
Individuals with suspected or confirmed diagnosis | Specific high cost medications |
Newborn screening Program [23] | • Phenylketonuria | All newborns | Screening, confirmation, follow up, dietary interventions |
Expanded newborn screening pilot [24] |
• Cystic fibrosis • Other inborn errors of metabolism |
All newborns | Under evaluation |